Date: 2012-05-31

Type of information: Licensing agreement

Compound: immunohistochemistry (IHC) primary antibody to detect the V600E BRAF mutation protein

Company: Ventana Medical Systems (USA), a member of the Roche Group (Switzerland) German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) (Germany) University Hospital Heidelberg (Germany)

Therapeutic area: Cancer - Oncology

Type agreement:


Action mechanism:

Disease: various cancers


Ventana Medical Systems, a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein. This new IHC diagnostic from Ventana will add to the bust Roche portfolio of BRAF diagnostics.
The BRAF protein plays a role in regulating cell signaling, and it has been shown to be mutated in many human cancers. The VENTANA antibody is being developed both as an in vitro diagnostic (IVD) and for research use only (RUO). These products are expected to be the first validated, commercially-available IHC antibodies capable of specifically detecting BRAF mutations.
Ventana subsidiary Spring Bioscience will commercialize a BRAF V600E RUO antibody to support research applications. This product will be commercially available May 31, 2012 through Spring Bioscience  and some of its distributors.
Ventana is currently developing the V600E BRAF mutation-specific antibody for IVD use to detect V600E BRAF mutation protein on its VENTANA BenchMark series of automated instruments utilized by thousands of anatomic pathology labs worldwide.

Financial terms:

Latest news:

Is general: Yes